GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sangamo Therapeutics Inc (NAS:SGMO) » Definitions » Cyclically Adjusted Revenue per Share

Sangamo Therapeutics (Sangamo Therapeutics) Cyclically Adjusted Revenue per Share : $0.82 (As of Mar. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Sangamo Therapeutics Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Sangamo Therapeutics's adjusted revenue per share for the three months ended in Mar. 2024 was $0.003. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.82 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Sangamo Therapeutics's average Cyclically Adjusted Revenue Growth Rate was -100.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 11.40% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 10.20% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 8.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Sangamo Therapeutics was 14.90% per year. The lowest was 5.10% per year. And the median was 9.45% per year.

As of today (2024-05-15), Sangamo Therapeutics's current stock price is $0.5679. Sangamo Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $0.82. Sangamo Therapeutics's Cyclically Adjusted PS Ratio of today is 0.69.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Sangamo Therapeutics was 69.82. The lowest was 0.35. And the median was 18.24.


Sangamo Therapeutics Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Sangamo Therapeutics's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sangamo Therapeutics Cyclically Adjusted Revenue per Share Chart

Sangamo Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.56 0.60 0.70 0.76 0.83

Sangamo Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.86 0.85 0.85 0.83 0.82

Competitive Comparison of Sangamo Therapeutics's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Sangamo Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sangamo Therapeutics's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sangamo Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Sangamo Therapeutics's Cyclically Adjusted PS Ratio falls into.



Sangamo Therapeutics Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Sangamo Therapeutics's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.003/129.4194*129.4194
=0.003

Current CPI (Mar. 2024) = 129.4194.

Sangamo Therapeutics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.153 100.560 0.197
201409 0.182 100.428 0.235
201412 0.218 99.070 0.285
201503 0.195 99.621 0.253
201506 0.120 100.684 0.154
201509 0.123 100.392 0.159
201512 0.130 99.792 0.169
201603 0.056 100.470 0.072
201606 0.053 101.688 0.067
201609 0.040 101.861 0.051
201612 0.126 101.863 0.160
201703 0.048 102.862 0.060
201706 0.114 103.349 0.143
201709 0.141 104.136 0.175
201712 0.154 104.011 0.192
201803 0.146 105.290 0.179
201806 0.220 106.317 0.268
201809 0.232 106.507 0.282
201812 0.262 105.998 0.320
201903 0.079 107.251 0.095
201906 0.153 108.070 0.183
201909 0.190 108.329 0.227
201912 0.473 108.420 0.565
202003 0.113 108.902 0.134
202006 0.155 108.767 0.184
202009 0.409 109.815 0.482
202012 0.182 109.897 0.214
202103 0.184 111.754 0.213
202106 0.194 114.631 0.219
202109 0.196 115.734 0.219
202112 0.192 117.630 0.211
202203 0.193 121.301 0.206
202206 0.198 125.017 0.205
202209 0.167 125.227 0.173
202212 0.165 125.222 0.171
202303 0.934 127.348 0.949
202306 0.039 128.729 0.039
202309 0.053 129.860 0.053
202312 0.011 129.419 0.011
202403 0.003 129.419 0.003

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Sangamo Therapeutics  (NAS:SGMO) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Sangamo Therapeutics's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=0.5679/0.82
=0.69

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Sangamo Therapeutics was 69.82. The lowest was 0.35. And the median was 18.24.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Sangamo Therapeutics Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Sangamo Therapeutics's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Sangamo Therapeutics (Sangamo Therapeutics) Business Description

Industry
Traded in Other Exchanges
Address
7000 Marina Boulevard, Brisbane, CA, USA, 94005
Sangamo Therapeutics Inc is a clinical-stage biotechnology company that translates ground-breaking science into genomic therapies transforming patients' lives using platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The company's product pipeline includes Hemophilia, Central Nervous System, HIV, Lysosomal Storage Disorders, and Hemoglobinopathies.
Executives
Biogen Inc. 10 percent owner 225 BINNEY STREET, CAMBRIDGE MA 02142
Beers Courtney director C/O SANGAMO THERAPEUTICS, INC., 7000 MARINA BOULEVARD, BRISBANE CA 94005
Margaret A Horn director 925 PAGE MILL ROAD, PALO ALTO CA 94304
Nathalie Dubois-stringfellow officer: SVP-Chief Development Officer C/O SANGAMO THERAPEUTICS, INC., 7000 MARINA BOULEVARD, BRISBANE CA 94005
John Markels director C/O SANGAMO THERAPEUTICS, INC., POINT RICHMOND TECH CTR, 501 CANAL BLVD., RICHMOND CA 94804
H Stewart Parker director
Biogen Ma Inc. 10 percent owner 225 BINNEY STREET, CAMBRIDGE MA 02142
Scott B. Willoughby officer: SVP, Gen. Counsel & Secretary 7000 MARINA BLVD, BRISBANE CA 94005
Gary Loeb officer: EVP & General Counsel 5885 HOLLIS ST., SUITE 100, EMERYVILLE CA 94608
Jason D. Fontenot officer: SVP, Chief Scientific Officer 7000 MARINA BLVD, BRISBANE CA 94005
Robert J. Schott officer: SVP, Head of Development 7000 MARINA BLVD, BRISBANE CA 94005
Rolf Andrew Ramelmeier officer: EVP, Technical Operations 7000 MARINA BLVD, BRISBANE CA 94005
Saira Ramasastry director 501 CANAL BLVD., RICHMOND CA 94804
Kenneth J. Hillan director C/O ACHAOGEN, INC., 7000 SHORELINE COURT, SUITE 371, SOUTH SAN FRANCISCO CA 94080
David Mark Mcclung officer: EVP Chief Business Officer 7000 MARINA BLVD, BRISBANE CA 94005

Sangamo Therapeutics (Sangamo Therapeutics) Headlines

From GuruFocus